NovaBridge Biosciences (NBP) Non-Current Deffered Revenue (2018 - 2023)

NovaBridge Biosciences (NBP) has 5 years of Non-Current Deffered Revenue data on file, last reported at $40.6 million in Q4 2023.

• Non-Current Deffered Revenue for Q4 2023 came in at $40.6 million, up 7.72% year-over-year; the trailing twelve-month figure through Dec 2023 was $40.6 million (up 7.72% YoY), and the FY2023 annual result was $41.2 million, up 1618.54% from the prior year.
• Non-Current Deffered Revenue grew to $40.6 million in Q4 2023 per NBP's latest filing, from $36.9 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $35.0 billion in Q4 2021 and troughed at $556172.6 in Q4 2019.
• A 4-year average of $5.9 billion and a median of $37.3 million in 2022 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2022 and 2023: Non-Current Deffered Revenue sank 99.89% in 2022, then jumped 1444.35% in 2023.
• A 4-year view of Non-Current Deffered Revenue shows it stood at $556172.6 in 2019, then jumped by 6299337.87% to $35.0 billion in 2021, then slumped by 99.89% to $37.7 million in 2022, then increased by 7.72% to $40.6 million in 2023.
• Business Quant data shows NBP's Non-Current Deffered Revenue at $40.6 million in Q4 2023, $36.9 million in Q2 2023, and $37.7 million in Q4 2022.